The aim of this study is to characterize the factors related to peptidoglycan metabolism in isogenic hVISA/VISA ST100 strains. Recently, we reported the increase in IS256 transposition in invasive hVISA ST100 clinical strains isolated from the same patient (D1 and D2) before and after vancomycin treatment and two laboratory VISA mutants (D23C9 and D2P11) selected from D2 in independent experiments. High performance liquid chromatography-mass spectrometry (HPLC-MS) analysis of peptidoglycan muropeptides showed increased proportion of monomeric muropeptides and a concomitant decrease in the proportion of tetrameric muropeptide in D2 and derived mutants when compared to the original strain D1. In addition, strain D2 and its derived mutants showed an increase in cell wall thickness with increased pbp2 gene expression. The VISA phenotype was not stable in D2P11 and showed a reduced autolysis profile. On the other hand, the mutant D23C9 differentiates from D2 and D2P11 in the autolysis profile, and pbp4 transcription profile. D2-derived mutants exhibited differences in the susceptibility to other antimicrobials. Our results highlight the possibility of selection of different VISA phenotypes from a single hVISA-ST100 genetic background.
Get full access to this article
View all access options for this article.
References
1.
HiramatsuK.1998. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med., 104:7S–10S.
2.
HowdenB.P., DaviesJ.K., JohnsonP.D., StinearT.P., and GraysonM.L.. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev., 23:99–139.
3.
HowdenB.P., PelegA.Y., and StinearT.P.. 2014. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect. Genet. Evol., 21:575–582.
4.
Boyle-VavraS., BerkeS.K., LeeJ.C., and DaumR.S.. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother., 44:272–277.
5.
SakoulasG., MoelleringR.C.Jr., and EliopoulosG.M.. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis., 42Suppl. 1:S40–S50.
6.
GalbuseraE., RenzoniA., AndreyD.O., MonodA., BarrasC., TortoraP., PolissiA., and KelleyW.L.. 2011. Site-specific mutation of Staphylococcus aureus VraS reveals a crucial role for the VraR-VraS sensor in the emergence of glycopeptide resistance. Antimicrob. Agents Chemother., 55:1008–1020.
7.
HowdenB.P., StinearT.P., AllenD.L., JohnsonP.D., WardP.B., and DaviesJ.K.. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother., 52:3755–3762.
8.
MatsuoM., CuiL., KimJ., and HiramatsuK.. 2013. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob. Agents Chemother., 57:5843–5853.
9.
ShojiM., CuiL., IizukaR., KomotoA., NeohH.M., WatanabeY., HishinumaT., and HiramatsuK.. 2011. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother., 55:3870–3881.
10.
WatanabeY., CuiL., KatayamaY., KozueK., and HiramatsuK.. 2011. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol., 49:2680–2684.
11.
JansenA., TurckM., SzekatC., NagelM., CleverI., and BierbaumG.. 2007. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol., 297:205–215.
12.
MakiH., McCallumN., BischoffM., WadaA., and Berger-BachiB.. 2004. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother., 48:1953–1959.
13.
McEvoyC.R., TsujiB., GaoW., SeemannT., PorterJ.L., DoigK., NgoD., HowdenB.P., and StinearT.P.. 2013. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression. Antimicrob. Agents Chemother., 57:3240–3249.
14.
Di GregorioS., FernandezS., PerazziB., BelloN., FamigliettiA., and MollerachM.. 2016. Increase in IS256 transposition in invasive vancomycin heteroresistant Staphylococcus aureus isolate belonging to ST100 and its derived VISA mutants. Infect. Genet. Evol., 43:197–202.
15.
HanakiH., Kuwahara-AraiK., Boyle-VavraS., DaumR.S., LabischinskiH., and HiramatsuK.. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother., 42:199–209.
16.
de JongeB.L., ChangY.S., GageD., and TomaszA.. 1992. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J. Biol. Chem., 267:11248–11254.
17.
GalleniM., LakayeB., LepageS., JaminM., ThammI., JorisB., and FrereJ.M.. 1993. A new, highly sensitive method for the detection and quantification of penicillin-binding proteins. Biochem. J., 291(Pt 1):19–21.
18.
MalachowaN., and DeLeoF.R.. 2010. Mobile genetic elements of Staphylococcus aureus. Cell. Mol. Life Sci., 67:3057–3071.
19.
SieradzkiK., and TomaszA.. 2003. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol., 185:7103–7110.
20.
BustinS.A., BenesV., GarsonJ.A., HellemansJ., HuggettJ., KubistaM., MuellerR., NolanT., PfafflM.W., ShipleyG.L., VandesompeleJ., and WittwerC.T.. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem., 55:611–622.
21.
HellemansJ., MortierG., De PaepeA., SpelemanF., and VandesompeleJ.. 2007. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol., 8:R19.
22.
ValihrachL., and DemnerovaK.. 2012. Impact of normalization method on experimental outcome using RT-qPCR in Staphylococcus aureus. J. Microbiol. Methods, 90:214–216.
23.
VandesompeleJ., De PreterK., PattynF., PoppeB., Van RoyN., De PaepeA., and SpelemanF.. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3:RESEARCH0034.
24.
Di RienzoJ.A., CasanovesF., BalzariniM.G., GonzalezL., TabladaM., and RobledoC.W.. 2013. InfoStat versión 2013. Available at www.infostat.com.ar (accessed July23, 2013).
25.
Aubry-DamonH., SoussyC.J., and CourvalinP.. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother., 42:2590–2594.
26.
KatoY., SuzukiT., IdaT., and MaebashiK.. 2010. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. J. Antimicrob. Chemother., 65:37–45.
27.
ChenH.Y., ChenC.C., FangC.S., HsiehY.T., LinM.H., and ShuJ.C.. 2011. Vancomycin activates sigma(B) in vancomycin-resistant Staphylococcus aureus resulting in the enhancement of cytotoxicity. PLoS One, 6:e24472.
28.
SchreiberF., SzekatC., JostenM., SahlH.G., and BierbaumG.. 2013. Antibiotic-induced autoactivation of IS256 in Staphylococcus aureus. Antimicrob. Agents Chemother., 57:6381–6384.
29.
HiramatsuK., KayayamaY., MatsuoM., AibaY., SaitoM., HishinumaT., and IwamotoA.. 2014. Vancomycin-intermediate resistance in Staphylococcus aureus. J. Glob. Antimicrob. Resist., 2:12.
30.
MemmiG., FilipeS.R., PinhoM.G., FuZ., and CheungA.. 2008. Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob. Agents Chemother., 52:3955–3966.
31.
SieradzkiK., and TomaszA.. 1999. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J. Bacteriol., 181:7566–7570.
32.
CafisoV., BertuccioT., SpinaD., PurrelloS., CampanileF., Di PietroC., PurrelloM., and StefaniS.. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One, 7:e29573.
33.
CuiL., TominagaE., NeohH.M., and HiramatsuK.. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother., 50:1079–1082.
34.
RinconS., PanessoD., DiazL., CarvajalL.P., ReyesJ., MunitaJ.M., and AriasC.A.. 2014. Resistance to “last resort” antibiotics in Gram-positive cocci: the post-vancomycin era. Biomedica, 34Suppl. 1:191–208.
35.
Lopez FurstM.J., de VediaL., FernandezS., GardellaN., GanahaM.C., PrietoS., CarboneE., ListaN., RotryngF., MoreraG.I., MollerachM., and StryjewskiM.E.. 2013. Prospective multicenter study of community-associated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus in Buenos Aires, Argentina. PLoS One, 8:e78303.
36.
GardellaN., PicassoR., PredariS.C., LasalaM., FoccoliM., BenchetritG., FamigliettiA., CatalanoM., MollerachM., and GutkindG.. 2005. Methicillin-resistant Staphylococcus aureus strains in Buenos Aires teaching hospitals: replacement of the multidrug resistant South American clone by another susceptible to rifampin, minocycline and trimethoprim-sulfamethoxazole. Rev. Argent. Microbiol., 37:156–160.
37.
VidaillacC., GardeteS., TewheyR., SakoulasG., KaatzG.W., RoseW.E., TomaszA., and RybakM.J.. 2013. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J. Infect. Dis., 208:67–74.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
